Rilotumumab

BIOLOGICAL8 trials

Sponsors

NantBioScience, Inc., Gynecologic Oncology Group, National Cancer Institute (NCI), Amgen, SWOG Cancer Research Network

Conditions

Advanced Malignant MesotheliomaColon CancerColorectal CancerEpithelial MesotheliomaGastric CancerGastrointestinal CancerMET PositiveMetastatic Colorectal Cancer

Phase 1

Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)

CompletedNCT00788957

NantBioScience, Inc.Colon Cancer, Colorectal Cancer, Gastrointestinal Cancer +2

Start: 2008-10-27End: 2010-07-23Updated: 2024-08-07

Phase 1/1b Study of Rilotumumab in Japanese Subjects With Advanced Solid Tumors or Advanced or Metastatic Gastric or GEJ

CompletedNCT01791374

AmgenPart 1- Advanced Solid Tumors, Part 2- Advanced or Metastatic Gastric Cancer, Part 2- Advanced or Metastatic GEJ

Start: 2012-11-30End: 2015-03-31Updated: 2016-02-29

Phase 2

Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

CompletedNCT01039207

Gynecologic Oncology GroupRecurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma

Start: 2010-10-31End: 2014-07-31Updated: 2017-09-07

AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma

WithdrawnNCT01105390

National Cancer Institute (NCI)Advanced Malignant Mesothelioma, Epithelial Mesothelioma, Recurrent Malignant Mesothelioma +1

Start: 2010-04-30Updated: 2013-08-02

Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches

TerminatedNCT02926638

SWOG Cancer Research NetworkMET Positive, Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7

Start: 2014-06-16End: 2016-10-12Updated: 2020-03-19

Phase 3

First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma

TerminatedNCT01697072

AmgenGastric Cancer

Start: 2012-10-31End: 2015-08-31Updated: 2016-02-09

A Phase 3 Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Gastric Cancer

TerminatedNCT02137343

AmgenGastric Cancer

Start: 2014-07-31End: 2015-06-30Updated: 2016-04-04

Unknown Phase

Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer

CompletedNCT02154490

SWOG Cancer Research NetworkRecurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7

Start: 2014-07-08End: 2022-04-15Updated: 2023-06-01

Related Papers

Abstract 5026: Dynamic changes in circulating protein levels reveal an association between ipilimumab and nivolumab combination treatment (SWOG Lung-MAP S1400I trial) with outcomes in squamous cell lung cancer

Cancer Research2022-06-15

Dynamic changes in serum analyte levels associated with clinical outcome in squamous cell lung cancer trial SWOG Lung-MAP S1400I of nivolumab ± ipilimumab.

Journal of Clinical Oncology2022-06-01

Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)

Journal for ImmunoTherapy of Cancer2021-08-0145 citations

Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer

JAMA Oncology2021-07-1596 citations

Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol.

2020-10-2790 citations

Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial

Cell Research2020-07-27298 citations

Lung-MAP (SWOG S1400): Design, implementation, and lessons learned from a biomarker-driven master protocol (BDMP) for previously-treated squamous lung cancer (sqNSCLC).

Journal of Clinical Oncology2020-05-201 citations

A phase II study of talazoparib (BMN 673) in patients with homologous recombination repair deficiency (HRRD) positive stage IV squamous cell lung cancer (Lung-MAP Sub-Study, S1400G).

Journal of Clinical Oncology2019-05-208 citations

First comprehensive report of impact of genomic alterations, chemotherapy, targeted therapy and immunotherapy on outcomes in the genomics driven squamous master protocol LungMAP.

Journal of Clinical Oncology2018-05-202 citations

Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.

2017-09-25260 citations

A Phase 1/1b tolerability study of rilotumumab alone or in combination with cisplatin and capecitabine in Japanese patients with gastric cancer

Japanese Journal of Clinical Oncology2017-08-093 citations

Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial

Genome Medicine2016-10-25275 citations

Lung-MAP (S1400) Lung Cancer Master Protocol: Accrual, demographics, and molecular markers.

Journal of Clinical Oncology2016-05-20

DI-033 Clinical response of rilotumumab in solid tumours

2016-02-14

Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study.

Journal of Clinical Oncology2015-05-20143 citations

Rilotumumab Exposure–Response Relationship in Patients with Advanced or Metastatic Gastric Cancer

Clinical Cancer Research2015-02-2632 citations

A phase 3, multicenter, randomized, double-blind, placebo-controlled study of rilotumumab in combination with cisplatin and capecitabine (CX) as first-line therapy for Asian patients (pts) with advanced MET-positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The RILOMET-2 trial.

Journal of Clinical Oncology2015-01-2036 citations

Randomized phase III study of panitumumab (pmab) vs. cetuximab (cmab) in chemorefractory wild-type (WT) <i>KRAS</i> exon 2 metastatic colorectal cancer (mCRC): Outcomes by hypomagnesemia (hypomag) in ASPECCT.

Journal of Clinical Oncology2015-01-203 citations

Exploratory <i>RAS</i> analysis of the phase Ib/II 20060447 trial of rilotumumab (R) or ganitumab (G) plus panitumumab (pmab) versus pmab alone in patients (pts) with previously treated metastatic colorectal cancer (mCRC).

Journal of Clinical Oncology2015-01-20

Safety, tolerability, and pharmacokinetics (PK) of rilotumumab (R) combined with cisplatin (C) and capecitabine (X) in Japanese patients (pts) with MET-positive metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.

Journal of Clinical Oncology2014-05-202 citations

1 more papers not shown